|0.73 0.02 (2.8%)||12-01 15:41|
|Targets||6-month :||0.91||1-year :||1.01|
|Resists||First :||0.78||Second :||0.87|
|Supports||First :||0.64||Second :||0.54|
|MAs||MA(5) :||0.7||MA(20) :||0.7|
|MA(100) :||0.93||MA(250) :||1.04|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||50.5||D(3) :||45.6|
|52-week||High :||1.92||Low :||0.64|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ QLGN ] has closed below upper band by 22.3%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.74 - 0.74||0.74 - 0.74|
|Low:||0.69 - 0.7||0.7 - 0.7|
|Close:||0.72 - 0.73||0.73 - 0.74|
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Mon, 27 Nov 2023
QLGN: Dosing Begins in Phase 1 Trial of QN-302… - Yahoo Finance
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||5 (M)|
|Shares Float||5 (M)|
|Held by Insiders||11.5 (%)|
|Held by Institutions||2.1 (%)|
|Shares Short||40 (K)|
|Shares Short P.Month||44 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.32|
|Profit Margin||0 %|
|Operating Margin||-314.1 %|
|Return on Assets (ttm)||-71.8 %|
|Return on Equity (ttm)||-290.7 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0.13|
|Sales Per Share||0.96|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-7 (M)|
|Levered Free Cash Flow||-3 (M)|
|Price to Book value||-2.29|
|Price to Sales||0.75|
|Price to Cash Flow||-0.56|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|